Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 3/20 | 0.63 |
| ▸ | MMP9 | P14780 | 11/20 | 0.63 |
| ▸ | MMP8 | P22894 | 4/20 | 0.63 |
| ▸ | MMP13 | P45452 | 1/20 | 0.63 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 3/20 | 0.47 |
| ▸ | MMP14 | P50281 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509337 | 1.00 | ITGAV (0.63) | ITGAVMMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL6669839 | 0.86 | ITGAV (0.66) | ITGAVMMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL6669846 | 0.86 | ITGAV (0.66) | ITGAVMMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL600044 | 0.85 | ITGAV (0.62) | ITGAVMMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL3898279 | 0.84 | ITGAV (0.67) | ITGAVMMP9L3MBTL1ITGA2SLC1A3 | |
| SCHEMBL27692486 | 0.84 | ITGAV (0.67) | ITGAVMMP13L3MBTL1ITGA2SLC1A3 | |
| SCHEMBL457771 | 0.83 | MMP9 (0.65) | ITGAVMMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL6670956 | 0.82 | POLB (0.66) | ITGAVMMP9MMP13ADAMTS4L3MBTL1 | |
| SCHEMBL5502394 | 0.82 | POLB (0.66) | ITGAVMMP9MMP13ADAMTS4L3MBTL1 | |
| SCHEMBL3969622 | 0.82 | ALDH1A1 (0.71) | ITGAVMMP9MMP13L3MBTL1ITGA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1457487-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) | 2004-09-02 | — | — | US | claimed |
| EP-2291077-A1 | PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS | Inspire Pharmaceuticals, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009154940-A1 | PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-1457487-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TYR, DDC, TARBP1 | ITGAV 4557/4885MMP9 1373/4885MMP8 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.